Dermatology company that develops topical products on for pharmaceutical and biotechnology companies
Developer of topical formulations and dermatology products for pharmaceutical and biotech clients
Dow Pharmaceutical Sciences was a dermatology R&D organization and an outsourced developer of topical dermatology products for external sponsors. At the time of its acquisition, the company’s product portfolio included a newly approved topical medication and a robust pipeline of five dermatology products, three of which were in Phase II clinical development. Dow Pharma also offered a full range of product development services including formulation and regulatory consulting, formulation optimization utilizing in-vitro permeation models, analytical support, cGMP clinical manufacturing and clinical labeling. The company conducted dermatology studies at clinical sites in the United States and Europe, and was based in Petaluma, California. Valeant Pharmaceuticals acquired Dow Pharmaceutical Sciences in December 2008 for $285 million in cash. The following year Valeant bought-out the rights to future milestone obligations from Dow shareholders for an additional one-time payment of $115 million.
